§ Federal grant opportunity · PAR-26-132
Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
National Institutes of Health is accepting applications for Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed). The deadline is Rolling / not published and the published award range is Award amount not published.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- Rolling / not published
- Award range
- Award amount not published
- Eligibility
- other, small businesses, public and state institutions of higher education, private institutions of higher education, nonprofits non higher education without 501c3, special district governments, for profit organizations other than small businesses, federally recognized native american tribal governments, county governments, nonprofits non higher education with 501c3, other native american tribal organizations, city or township governments, public and indian housing authorities, state governments, independent school districts
- Geography
- United States
- Focus areas
- Health
- Opportunity number
- PAR-26-132
Program overview
The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research on Alzheimer's disease (AD) and AD-related dementias (ADRD) drug target validation and early-stage drug discovery against novel targets. This NOFO will utilize the U01 activity code. The NOFO will support rigorous preclinical AD/ADRD drug target validation and early-stage drug discovery of small molecules, biologic, and emerging therapeutic modalities. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Investigators with expertise and insights into AD/ADRD and drug discovery are encouraged to begin to consider applying for this new NOFO.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before Rolling / not published, allowing time for registration and validation.
Related grant opportunities
- Notice of Funding Opportunity for the Fiscal Year 2025 and 2026 Consolidated Rail Infrastructure and Safety Improvements Program
- Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional)
- Network of the National Library of Medicine Coordinating Center (U24 Clinical Trial Optional)
- Biomechanics and Mechanobiology (BMMB)
- Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.